Cortellini A, Cannita K, Tiseo M, Cortinovis DL, et al. Post-progression outcomes of NSCLC patients with PD-L1 expression >/= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer 2021;148:24-35.
PMID: 33721704